Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2024-03-06 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
第二届监事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 科兴生物制药股份有限公司 regarding the approval of a related party transaction agreement. It includes details about the meeting date, attendance, and voting results. It does not contain financial statements or detailed financial data, nor is it a full report or presentation. It is an official announcement of a board/management decision related to corporate governance and internal approvals. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on a board resolution, not a full report or regulatory filing.
2024-03-06 Chinese
关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program, detailing the number of shares repurchased, prices, total funds used, and compliance with relevant regulations. It does not contain financial statements or detailed financial analysis but focuses on the company's buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's repurchase of its own shares.
2024-02-29 Chinese
关于实际控制人兼董事长、董事及高级管理人员增持股份的进展公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of share purchases by the company's actual controller, chairman, directors, and senior management. It details the number of shares acquired, the amounts spent, and the percentage of total shares held. The content focuses on insider share transactions by company executives and does not contain financial statements or performance data. It is not a full report but a disclosure of personal share dealings by directors and senior management. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 2569 characters, which is consistent with a detailed announcement but not a full financial report.
2024-02-29 Chinese
关于回购股份事项前十大股东和前十大无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 科兴生物制药股份有限公司 regarding the top ten shareholders and top ten unrestricted shareholders before a share repurchase plan. It references a board meeting approving a share buyback and provides detailed shareholding information. The document does not contain financial statements or detailed financial analysis but focuses on shareholding changes related to a share repurchase. This fits the category of Transaction in Own Shares (POS), which covers company announcements about buying back or selling its own shares.
2024-02-27 Chinese
关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about its first share repurchase through centralized bidding on the stock exchange. It details the number of shares repurchased, prices, total funds used, and references the regulatory rules governing share buybacks. The document does not contain financial statements or detailed financial analysis but focuses on the share repurchase transaction itself. This matches the definition of a Transaction in Own Shares (POS) filing, which reports the company's buyback of its own shares.
2024-02-26 Chinese
2023年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023年度业绩快报公告" which translates to "2023 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2023, including revenue, profit, and other financial indicators. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be disclosed in the company's full annual report. The document is relatively short (1653 characters) and serves as a quick summary or earnings flash rather than a full detailed report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is also not a Report Publication Announcement (RPA) because it contains actual preliminary financial data, not just a notice of report availability. FY 2023
2024-02-23 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.